Anticoagulation in COVID-19: not strong for too long? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Anaesthesia Critical Care & Pain Medicine Année : 2021

Anticoagulation in COVID-19: not strong for too long?

Résumé

Several randomised controlled trials are currently underway to evaluate the value of increasing the dose of prophylactic anticoagulation in critically ill COVID-19 patients, either at an intermediate or therapeutic dose, in order to decrease thrombotic complications, organ failure and possibly reduce mortality in these patients.
Fichier principal
Vignette du fichier
Anticoagulation in COVID.pdf (210.8 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04370740 , version 1 (03-01-2024)

Identifiants

Citer

Charles Tacquard, Alexandre Mansour, Alexandre Godon, Yves Gruel, Sophie Susen, et al.. Anticoagulation in COVID-19: not strong for too long?. Anaesthesia Critical Care & Pain Medicine, 2021, 40 (2), pp.100857. ⟨10.1016/j.accpm.2021.100857⟩. ⟨hal-04370740⟩
10 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More